{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:20:55Z","timestamp":1770412855018,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30973669\/H3004"],"award-info":[{"award-number":["30973669\/H3004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biotechnology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jbiotec.2014.06.017","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T22:57:07Z","timestamp":1404255427000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A novel bispecific antibody targeting tumor necrosis factor \u03b1 and ED-B fibronectin effectively inhibits the progression of established collagen-induce arthritis"],"prefix":"10.1016","volume":"186","author":[{"given":"Mengyuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbiotec.2014.06.017_bib0005","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.0818-9641.2003.01185.x","article-title":"Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis","volume":"81","author":"Campbell","year":"2003","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cyto.2004.07.012","article-title":"New cytokine therapeutics for inflammatory bowel disease","volume":"28","author":"Stokkers","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00063030-200519010-00006","article-title":"TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis","volume":"19","author":"Tobin","year":"2005","journal-title":"BioDrugs"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0020","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(00)03239-6","article-title":"Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms","volume":"356","author":"Van den Bosch","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0025","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","article-title":"New drugs for rheumatoid arthritis","volume":"350","author":"Olsen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0030","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/rheumatology\/39.10.1139","article-title":"Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients","volume":"39","author":"Choy","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","article-title":"Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease","volume":"12","author":"Tabrizi","year":"2010","journal-title":"AAPS J."},{"issue":"Suppl 1","key":"10.1016\/j.jbiotec.2014.06.017_bib0040","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s10875-012-9768-y","article-title":"The immunologic functions of the neonatal Fc receptor for IgG","volume":"33","author":"Rath","year":"2013","journal-title":"J. Clin. Immunol."},{"issue":"7","key":"10.1016\/j.jbiotec.2014.06.017_bib0045","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/acr.22281","article-title":"Risk of hospitalized bacterial infections associated with biologic treatment among U.S. Veterans with Rheumatoid Arthritis","volume":"66","author":"Curtis","year":"2014","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0050","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0055","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2011.04.010","article-title":"Anti-TNF therapy: safety aspects of taking the risk","volume":"10","author":"Rosenblum","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.it.2003.12.001","article-title":"Antibodies and gene therapy: teaching old \u2018magic bullets\u2019 new tricks","volume":"25","author":"Sanz","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0065","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.tibtech.2010.03.007","article-title":"Multivalent antibodies: when design surpasses evolution","volume":"28","author":"Cuesta","year":"2010","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0070","first-page":"225","article-title":"Pharmacokinetics and biodistribution of genetically-engineered antibodies","volume":"42","author":"Colcher","year":"1998","journal-title":"Q. J. Nucl. Med."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0075","first-page":"1","article-title":"Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials","author":"Bykerk","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0080","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1083\/jcb.108.3.1139","article-title":"A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors","volume":"108","author":"Carnemolla","year":"1989","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ijc.10662","article-title":"Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin","volume":"102","author":"Borsi","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0090","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0014-5793(90)80664-5","article-title":"Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor","volume":"261","author":"Borsi","year":"1990","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0095","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/j.1460-2075.1987.tb02509.x","article-title":"Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon","volume":"6","author":"Zardi","year":"1987","journal-title":"EMBO J."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0100","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1083\/jcb.109.2.903","article-title":"Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat","volume":"109","author":"Ffrench-Constant","year":"1989","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0105","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ijc.2910590507","article-title":"The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis","volume":"59","author":"Castellani","year":"1994","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0110","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1158\/1078-0432.CCR-06-0210","article-title":"Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors","volume":"12","author":"Moosmayer","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0115","doi-asserted-by":"crossref","first-page":"21769","DOI":"10.1074\/jbc.273.34.21769","article-title":"Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel","volume":"273","author":"Pini","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0120","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2008-06-160416","article-title":"Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients","volume":"113","author":"Sauer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0125","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/rheumatology\/38.11.1099","article-title":"Increased Ed-B fibronectin plasma levels in spondyloarthropathies: comparison with rheumatoid arthritis patients and a healthy population","volume":"38","author":"Claudepierre","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2310\/7290.2009.00030","article-title":"Extra domain B fibronectin as a target for near-infrared fluorescence imaging of rheumatoid arthritis affected joints in vivo","volume":"8","author":"Vollmer","year":"2009","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00296-003-0316-1","article-title":"Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis","volume":"24","author":"Kriegsmann","year":"2004","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0140","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1186\/ar2115","article-title":"Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis","volume":"9","author":"Trachsel","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0145","doi-asserted-by":"crossref","first-page":"R142","DOI":"10.1186\/ar2814","article-title":"Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis","volume":"11","author":"Schwager","year":"2009","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.jbiotec.2014.06.017_bib0210","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1002\/art.30650","article-title":"Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritis","volume":"63","author":"Kamperidis","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/BA20050194","article-title":"One-step on-column purification and refolding of a single-chain variable fragment (scFv) antibody against tumour necrosis factor alpha","volume":"43","author":"Liu","year":"2006","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0160","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1042\/BJ20070149","article-title":"Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb","volume":"406","author":"Liu","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/BA20070229","article-title":"A novel bivalent single-chain variable fragment (scFV) inhibits the action of tumour necrosis factor alpha","volume":"50","author":"Liu","year":"2008","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0170","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.4049\/jimmunol.142.11.3884","article-title":"Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors","volume":"142","author":"Sheehan","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0175","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/283666a0","article-title":"Immunisation against heterologous type II collagen induces arthritis in mice","volume":"283","author":"Courtenay","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0180","doi-asserted-by":"crossref","first-page":"R122","DOI":"10.1186\/ar748","article-title":"Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats","volume":"5","author":"Campo","year":"2003","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0185","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.0105-2896.2009.00854.x","article-title":"Fibroblast-like synoviocytes in inflammatory arthritis pathology: the emerging role of cadherin-11","volume":"233","author":"Chang","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0190","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.drup.2004.03.001","article-title":"Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives","volume":"7","author":"Eichhorn","year":"2004","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0195","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/bjc.1992.144","article-title":"Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab\u2032)2 fragments in experimental ovarian cancer","volume":"65","author":"Molthoff","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0200","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1359-6101(02)00027-8","article-title":"IL-6 in autoimmune disease and chronic inflammatory proliferative disease","volume":"13","author":"Ishihara","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jbiotec.2014.06.017_bib0205","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.4049\/jimmunol.145.12.4181","article-title":"Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production","volume":"145","author":"Seckinger","year":"1990","journal-title":"J. Immunol."}],"container-title":["Journal of Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165614002983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165614002983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T22:30:48Z","timestamp":1689373848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168165614002983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":41,"alternative-id":["S0168165614002983"],"URL":"https:\/\/doi.org\/10.1016\/j.jbiotec.2014.06.017","relation":{},"ISSN":["0168-1656"],"issn-type":[{"value":"0168-1656","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel bispecific antibody targeting tumor necrosis factor \u03b1 and ED-B fibronectin effectively inhibits the progression of established collagen-induce arthritis","name":"articletitle","label":"Article Title"},{"value":"Journal of Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbiotec.2014.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}